February 272023

Amsterdamthe Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company dedicated to improving the lives of people living with serious autoimmune diseases, today announced that members of management will be attending several upcoming investor conferences in March:

• Cowen 43rd Annual Health Conference. Fireside chat on Monday, March 6, 2023 at 10:30 am ET in Boston, MA.
• Raymond James 44th Annual Institutional Investors Conference. Presentation on Tuesday, March 7, 2023 at 1:05 p.m. ET in Orlando, FL.

More information on these events is available in the Investors section of the argenx website at argenx.com/investors.

About Argentx

argenx is a global immunology company dedicated to improving the lives of people living with serious autoimmune diseases. In collaboration with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate breakthrough discoveries in immunology into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first and only neonatal Fc receptor (FcRn) blocker approved in the US, EU and Japan. For more information visit www.argenx.com and keep following us LinkedIn, TwitterAnd Instagram.

For more information please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Investors:

Beth Del Giacco
bdelgiacco@argenx.com